Costs and quality of life of patients with multiple sclerosis in Europe
- 18 May 2006
- journal article
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 77 (8), 918-926
- https://doi.org/10.1136/jnnp.2006.090365
Abstract
Objective: To assess overall resource consumption, work capacity and quality of life of patients with multiple sclerosis in nine European countries. Methods: Information on resource consumption related to multiple sclerosis, informal care by relatives, productivity losses and overall quality of life (utility) was collected with a standardised pre-tested questionnaire from 13 186 patients enrolled in national multiple sclerosis societies or followed up in neurology clinics. Information on disease included disease duration, self-assessed disease severity and relapses. Mean annual costs per patient (€, 2005) were estimated from the societal perspective. Results: The mean age ranged from 45.1 to 53.4 years, and all levels of disease severity were represented. Between 16% and 29% of patients reported experiencing a relapse in the 3 months preceding data collection. The proportion of patients in early retirement because of multiple sclerosis ranged from 33% to 45%. The use of direct medical resources (eg, hospitalisation, consultations and drugs) varied considerably across countries, whereas the use of non-medical resources (eg, walking sticks, wheel chairs, modifications to house and car) and services (eg, home care and transportation) was comparable. Informal care use was highly correlated with disease severity, but was further influenced by healthcare systems and family structure. All types of costs increased with worsening disease. The total mean annual costs per patient (adjusted for gross domestic product purchasing power) were estimated at €18 000 for mild disease (Expanded Disability Status Scale (EDSS) 7.0). Utility was similar across countries at around 0.70 for a patient with an EDSS of 2.0 and around 0.45 for a patient with an EDSS of 6.5. Intangible costs were estimated at around €13 000 per patient.Keywords
This publication has 20 references indexed in Scilit:
- Use of Cost-Effectiveness Analysis in Health-Care Resource Allocation Decision-Making: How Are Cost-Effectiveness Thresholds Expected to Emerge?Value in Health, 2004
- Cost-Analysis of Relapsing-Remitting Multiple Sclerosis in Italy after the???Introduction of New Disease-Modifying AgentsClinical Drug Investigation, 2004
- Cost-utility of interferon β 1b in the treatment of patients with active relapsing-remitting or secondary progressive multiple sclerosisThe European Journal of Health Economics, 2003
- Cost-Effectiveness Analysis of Interferon Beta in Multiple Sclerosis: A Markov Process AnalysisValue in Health, 2002
- COST-UTILITY ANALYSIS OF INTERFERON BETA-1B IN SECONDARY PROGRESSIVE MULTIPLE SCLEROSISInternational Journal of Technology Assessment in Health Care, 2000
- Population based cost utility study of interferon beta-1b in secondary progressive multiple sclerosisBMJ, 1999
- Utilisation and cost of professional care and assistance according to disability of patients with multiple sclerosis in Flanders (Belgium)Journal of Neurology, Neurosurgery & Psychiatry, 1998
- The Economic Cost of Multiple Sclerosis in Sweden in 1994PharmacoEconomics, 1998
- The friction cost method for measuring indirect costs of diseaseJournal of Health Economics, 1995
- EuroQol - a new facility for the measurement of health-related quality of lifeHealth Policy, 1990